Brilliant Violet 785 anti-human CD196 CCR6 Antibody anti-CD196 - G034E3,BioLegend,353421

Host

Mouse

Reactivity

Human, Cynomolgus, Rhesus

Application

FC - Quality tested

Platform ID

BAB743533721

BioLegend

Headquarters

8999 BioLegend Way San Diego, CA 92121 United States

Contact

Tel: 1-858-455-9588
Fax: +49 (4131) 7023913

Email:

Product Specifications
Scientific Background

Specifications

NameBrilliant Violet 785 anti-human CD196 CCR6 Antibody anti-CD196 - G034E3
Cat. No.353421
HostMouse
RRIDAB_2561372 (BioLegend Cat. No. 353421)AB_2563660 (BioLegend Cat. No. 353422)
IsotypeMouse IgG2b, κ
ReactivityHuman, Cynomolgus, Rhesus
ApplicationFC - Quality tested
ClonalityMonoclonal
Clone NumberG034E3
ConcentrationLot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in ourCertificate of Analysisonline tool.)
TargetCD196
ImmunogenCCR6-transfected cells
PurityThe antibody was purified by affinity chromatography and conjugated with Brilliant Violet 785™ under optimal conditions.
FormulationPhosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
StorageThe antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light.Do not freeze.
Regulatory StatusResearch Use Only

Scientific Background

CCR6, also known as CD196, is a chemokine receptor that is expressed on immature dendritic cells, B lymphocytes, and memory T cells. CCR6 binds CCL20, although members of the β defensin family also bind CCR6 with a lower affinity. CCR6 positive cells, and its ligand CCL20, have been detected in numerous organs, especially the secondary lymphoid organ. CCL20 is selectively made by the follicle-associated epithelium (FAE) overlying Peyers Patches (PPs) and isolated lymphoid follicles (ILFs). CCL20 contributes to the recruitment of CCR6-expressing B cells to these structures. In humans, CCR6 can function to mediate arrest of T cells on dermal endothelial cells and is highly expressed on T cells resident in both normal and psoriatic skin. CCR6 and/or CCL20 have been implicated in the pathogenesis of rheumatoid arthritis and inflammatory bowel disease. Human T cells that are able to produce IL-17 express CCR6. It suggests that CCL20 and CCR6 have a role in inflammatory diseases by recruiting Th17 cells to target tissues.

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.